PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the company will host a webcast conference call to report its first quarter 2026 financial results and provide an update on the company's ...
Looking back on design software stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including PTC ...
PTC Therapeutics is keeping its regulatory teams busy. In its third-quarter results, the biotech reported pushback against its plans to seek approval for two molecules based on existing data—and saw ...
PTC Therapeutics, Inc. (NASDAQ:PTCT) on Monday announced results from the Phase 2 PIVOT-HD study of PTC518 (votoplam) in Stage 2 and Stage 3 Huntington’s disease (HD) patients. Huntington’s disease is ...
PTC today announced it will demonstrate how Bobcat, a leading global manufacturer of compact equipment, can leverage the ...
PTC announced the acquisition of the cloud-native computer-aided Manufacturing (CAM) solution, CloudMilling. Terms of the transaction were not disclosed. The UK-based father and son team, which had ...
Welcoming back in-person delegates to its LiveWorx conference for the first time since the pre-pandemic days of 2019, and noting that the company finds itself in one of the greatest periods of change ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results